Valuation: ABVC BioPharma, Inc.

Market Cap 27.19M 24.28M 22.41M 20.33M 38.07M 2.58B 38.66M 270M 107M 1.35B 102M 99.87M 4.26B P/E 2024
-1.4x
P/E 2025 -5.42x
Enterprise Value 29.92M 26.71M 24.66M 22.37M 41.89M 2.84B 42.54M 297M 118M 1.49B 112M 110M 4.69B EV / Sales 2024
19.8x
EV / Sales 2025 -
Free-Float
79.73%
Yield 2024 *
-
Yield 2025 -
1 day-0.70%
1 week+11.53%
Current month-1.89%
1 month-10.34%
3 months-11.86%
6 months-11.86%
Current year-51.17%
1 week 0.89
Extreme 0.8918
1.07
1 month 0.89
Extreme 0.8918
1.18
Current year 0.71
Extreme 0.7069
2.43
1 year 0.71
Extreme 0.7069
3.06
3 years 0.4
Extreme 0.4
5.48
5 years 0.4
Extreme 0.4
116.9
10 years 0.4
Extreme 0.4
378
Manager TitleAgeSince
Chief Executive Officer 40 20/06/2023
Chief Tech/Sci/R&D Officer 72 14/06/2023
Director TitleAgeSince
Chairman 39 30/06/2015
Director/Board Member 65 22/11/2017
Director/Board Member 55 22/11/2017
Date Insider Type Main position Quantity % Market Cap. Importance
20/05/22 Other

Chairman

7,908,805 26.0954%
02/08/21 Other

Director

5,949 0.0243%
02/08/21 Other

Chief Executive Officer

18,404 0.0752%
Change 5-day change 1-year change 3-year change Capi.($)
-0.70%+11.53%-63.12%+14.14% 27.19M
+2.41%-6.33%+43.43%+71.02% 63.29B
-0.15%+3.11%+10.29%+72.56% 54.89B
+0.57%+4.64%+12.82%+89.79% 53.28B
+0.37%+3.07%+28.23%+51.53% 45.81B
-1.21%+0.95%+20.44%+128.58% 43.46B
-0.37%-1.20%+252.94%+568.54% 40.23B
+0.05%+6.75%+14.48%+56.75% 33.45B
+1.19%-5.84%+27.86%-0.65% 23.7B
-0.38%+4.55%+37.71%+28.10% 23.76B
Average +0.18%+1.53%+38.51%+108.04% 38.19B
Weighted average by Cap. +0.38%+0.55%+48.16%+122.11%

Financials

2024 2025
Net sales 510K 455K 420K 381K 714K 48.38M 725K 5.06M 2M 25.32M 1.91M 1.87M 79.91M -
Net income -4.9M -4.38M -4.04M -3.67M -6.87M -465M -6.97M -48.66M -19.28M -244M -18.4M -18.01M -769M -7.91M -7.06M -6.52M -5.91M -11.07M -751M -11.24M -78.5M -31.1M -393M -29.67M -29.04M -1.24B
Net Debt 2.88M 2.57M 2.38M 2.16M 4.04M 274M 4.1M 28.61M 11.33M 143M 10.81M 10.58M 452M 2.73M 2.43M 2.25M 2.04M 3.82M 259M 3.88M 27.07M 10.72M 136M 10.23M 10.02M 428M
Projected Income Statement - Annual - ABVC BioPharma, Inc.
Logo ABVC BioPharma, Inc.
ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer.
Employees
-
Date Price Change Volume
23/10/26 US$1.040 -0.70% 22,010
22/10/26 US$1.047 +4.73% 45,691
21/10/26 US$1.000 +7.53% 49,336
20/10/26 US$0.9300 +2.20% 11,820
19/10/26 US$0.9100 -0.86% 26,892
  1. Stock Market
  2. Stocks
  3. ABVC Stock